Bioness® StimRouter™ Neuromodulation System for Chronic Pain Therapy

Completed · Not applicable

Conditions studied: Chronic Pain

In brief

The purpose of this study is to investigate whether the StimRouter (SR) electrical stimulation therapy leads to clinically important pain relief in patients with chronic intractable pain of peripheral nerve origin after three months of treatment. At the same time, this study will gather information on side effects associated with the StimRouter electrical stimulation therapy.

Key facts

Study ID

NCT01592344

Run by

Bioness Inc

People needed

94

Starts

2012-04-01

Expected to finish

2015-07-01

Last updated by the study team

2016-04-11

Who can join

Age: 22 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥ 22 years) suitable for an implanted electrode for pain relief.
• Subjects who are able to give informed consent and to understand and comply with study requirements.
• Subjects who have severe intractable chronic pain of peripheral nerve origin associated with post traumatic/post surgical neuralgia for ≥ 3 months (i.e., intractable to pain medication).
• Subjects who are able to tolerate skin surface stimulation (TENS).
• Subjects who have a worst chronic pain level in the last 24 hours ≥ 5/10 (on 0-10 NRS) where such pain is attributable to a lesion or disease of the somatosensory nervous system.
• Subjects who are on a stable dose of pain medications for at least four weeks prior to screening and willing and able to maintain an equivalent dosage of their current pain medications from randomization to 3-month follow-up.

You may not qualify if…

• Subjects who are not willing and able to maintain stable dosages of their pain medications from randomization to 3-month follow-up.
• Subjects with a pain condition that could be confused with their peripheral neuropathic pain or that is more severe than their peripheral neuropathic pain.
• Subjects who, for implantation in the trunk, have an implanted demand-type cardiac pacemaker or defibrillator.
• Subjects who have a metal implant in the area for StimRouter implantation without Sponsor approval. Maintain a minimum separation distance of 6 inches (15 cm) between the StimRouter system and all other active implanted devices and metallic implants.
• Subjects who require, or are likely to require, diathermy at the implant site.
• Subjects who require, or are likely to require, therapeutic ultrasound at the implant site.
• Subjects who have a cancerous lesion present near the target stimulation point or near to where the StimRouter user patch will adhere.
• Subjects who are known or suspected to have a nickel allergy.
• Subjects with bleeding disorders or active anticoagulation that cannot be stopped for a few days close to the time of the surgical procedure.
• Subjects who decline to provide written consent or follow-up.
• Subjects who are pregnant, plan on becoming pregnant, or are breastfeeding during the study period. Subjects who are female of child-bearing potential must have a negative pregnancy test at baseline visit and, if sexually active, must be using a medically acceptable method of contraception for the duration of the study participation.
• Subjects who have an active systemic infection or are immunocompromised.
• Subjects who have an active or existing skin disorder or irritation, which, at the physician's discretion, precludes the use of skin gel electrodes.
• Subjects who currently require or are likely to require Magnetic Resonance Imaging (MRI) within the MRI exclusion zone: the entire StimRouter lead must be at least 50 cm from the center of the MR system's bore (the iso-center) and at least 16 cm outside of the MR coil measured from the edge of the MR coil.
• Subjects who have a history of adverse reactions to local anesthetic (e.g., lidocaine).
• Subjects who are participating in any other study that could affect the outcome of the StimRouter study, such as a spinal stimulation study, without Sponsor approval.
• Subjects who are in litigation or who have pending or an active worker's compensation claim.
• Subjects with less than one year of life expectancy.

Where it is running

• Arizona Pain Specialists — Scottsdale, Arizona, United States
• Neurovations — Napa, California, United States
• Neuro-Therapeutics, Inc. — Pasadena, California, United States
• The Spine Institute, Center for Spinal Restoration — Santa Monica, California, United States
• Holy Cross Orthopedic Institute — Fort Lauderdale, Florida, United States
• Shands Jacksonville Medical Center, Dept of Neurology Research — Jacksonville, Florida, United States
• Millennium Pain Center — Bloomington, Illinois, United States
• Premier Pain Centers, LLC — Shrewsbury, New Jersey, United States
• The Center for Clinical Research — Winston-Salem, North Carolina, United States
• Cleveland Clinic — Cleveland, Ohio, United States
• Virginia Mason Medical Center — Seattle, Washington, United States
• Center for Pain Relief, St. Francis Hospital — Charleston, West Virginia, United States
• The Center for Pain Relief at St. Mary's Medical Center — Huntington, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.